Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals
- 1 July 2007
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 18 (6), 693-696
- https://doi.org/10.1097/cad.0b013e32803a46fe
Abstract
The hepatic isoform 1A1 of uridine diphosphate glucuronosyltransferase is responsible for glucuronidation and detoxification of SN-38, the active metabolite of irinotecan. The presence of an additional TA repeat in the TATA sequence of the UGT1A1 promoter leads to a significant decrease in SN-38 glucuronidation. Patients with the UGT1A1 (TA)7 allele are more likely to experience severe neutropenia and diarrhea following irinotecan chemotherapy. We assessed the distribution of the UGT1A1 (TA)n polymorphism in healthy male and female US residents of European and Asian descent. We used a fluorescent polymerase chain reaction-based assay to detect UGT1A1 (TA)n polymorphisms in 138 healthy volunteers (56 Caucasians, 37 Chinese, 37 Filipino and eight Japanese) between the ages of 18 and 65 years. The chi-test was used to assess between-group differences in the distribution of UGT1A1 (TA)n genotypes. The UGT1A1 (TA)6/6 genotype was significantly more common in Asians than in Caucasians (76 vs. 46%), whereas the (TA)6/7 (39 vs. 20%) and (TA)7/7 (13 vs. 5%) genotypes were more common in Caucasians than in Asians. Genotype distributions did not differ significantly between men and women in either group. The UGT1A1 (TA)5/5 genotype was detected in one Caucasian woman. In conclusion, consistent with previous reports, the UGT1A1 (TA)7/7 genotype was significantly more common in Caucasians than in Asians. UGT1A1 (TA)n/n genotype distribution did not vary with sex in individuals of European or Asian descent.Keywords
This publication has 22 references indexed in Scilit:
- Influence of Genetic Variants inUGT1A1andUGT1A9on the In Vivo Glucuronidation of SN-38The Journal of Clinical Pharmacology, 2004
- Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of IrinotecanJournal of Clinical Oncology, 2004
- UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityThe Pharmacogenomics Journal, 2002
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 2000
- Racial variability in the UDP-glucuronosyltransferase 1 ( UGT1A1 ) promoter: A balanced polymorphism for regulation of bilirubin metabolism?Proceedings of the National Academy of Sciences, 1998
- Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.Journal of Clinical Investigation, 1998
- Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reportsAnnals of Oncology, 1997
- Clinical Pharmacokinetics of IrinotecanClinical Pharmacokinetics, 1997
- The Genetic Basis of the Reduced Expression of Bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's SyndromeNew England Journal of Medicine, 1995